https://doi.org/10.4081/reumatismo.2025.1744
Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease
Submitted: 13 May 2024
Accepted: 22 July 2024
Published: 22 January 2025
Accepted: 22 July 2024
Abstract Views: 21
PDF: 9
SUPPLEMENTARY MATERIAL: 5
SUPPLEMENTARY MATERIAL: 5
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Objective. To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with immunoglobulin-G4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-CoV-2 infection in IgG4-RD patients.
Methods. Patients with IgG4-RD in follow-up before the onset of the SARS-CoV-2 pandemic were contacted by telephone and asked to answer an ad hoc questionnaire regarding their vaccination status against SARS-CoV-2 and related AEs following vaccination. The occurrence and the outcome of SARS-CoV-2 infection were also recorded. The same questionnaire was proposed to healthy controls (HC).
Results. 20 patients and 40 HC were enrolled. In the patient’s cohort, 90% were vaccinated with at least one dose; among them, 9 reported AEs: 44.4% systemic and 22.2% local. Within the HC group, 100% were vaccinated with at least one dose. 13 out of 40 HC had systemic AEs (50%), and 27 (67.5%) reported local AEs. Neither in IgG4-RD nor in HC, serious adverse reactions were observed. Among the patient’s cohort, 60% contracted SARS-CoV-2 infection, and 41.67% were on immunosuppressants at the time of the infection. One patient presented with severe COVID-19. No disease flares following vaccination or infection were reported.
Conclusions. Results from our study indicate a good adherence to the vaccination campaign against SARS-CoV-2 in patients with IgG4-RD and support a relatively good safety profile of this vaccine. Compared to controls, patients with IgG4-RD reported slightly more systemic AEs and fewer local AEs. A similar rate of COVID-19 development was observed between IgG4-RD patients and HC.
Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol 2020; 16: 702-14.
DOI: https://doi.org/10.1038/s41584-020-0500-7
Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Peach E, Bythell M, et al. COVID-19 infection, admission and death among people with rare autoimmune rheumatic disease in England: results from the RECORDER project. Rheumatology 2022; 61: 3161-71.
DOI: https://doi.org/10.1093/rheumatology/keab794
Chen Y, Dong Y, Cai S, Ye C, Dong L. Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China. Semin Arthritis Rheum 2020; 50: 559-63.
DOI: https://doi.org/10.1016/j.semarthrit.2020.04.015
Tang RSY, Sattayalertyanyong O, Kuo YT, Park KH, Anastassiades C, Ligresti D, et al. Impact of COVID-19 infection and vaccination in pancreatobiliary IgG4-related disease patients: an international multicenter study. J Gastroenterol Hepatol 2023; 38: 584-9.
DOI: https://doi.org/10.1111/jgh.16100
Ramirez GA, Lanzillotta M, Ebbo M, Fernandez-Codina A, Mancuso G, Orozco-Galvez O, et al. Clinical features and outcomes of COVID-19 in patients with IgG4-related disease: a European multi-centre study. Rheumatology 2022; 61: e109-11.
DOI: https://doi.org/10.1093/rheumatology/keab930
Umehara H, Okazaki K, Kawa S, Takahashi H, Goto H, Matsui S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 2021; 31: 529-33.
DOI: https://doi.org/10.1080/14397595.2020.1859710
Landewé RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester GR, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis 2022; 81: 1628-39.
DOI: https://doi.org/10.1136/annrheumdis-2021-222006
Priori R, Pellegrino G, Colafrancesco S, Alessandri C, Ceccarelli F, Di Franco M, et al. SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Ann Rheum Dis 2021; 80: 953-4.
DOI: https://doi.org/10.1136/annrheumdis-2021-220059
Simoncelli E, Conticini E, Colafrancesco S, Gattamelata A, Spinelli FR, Garufi C, et al. Multicentre case-control study evaluating the safety of anti-SARS-CoV-2 vaccines in a cohort of patients with systemic vasculitis. Clin Exper Rheumatol 2023; 41: 922-7.
DOI: https://doi.org/10.55563/clinexprheumatol/if8nka
Inanc N, Kostov B, Priori R, Flores-Chavez A, Carubbi F, Szántó A, et al; Sjögren Big Data Consortium. Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome. Clin Exp Rheumatol 2022; 40: 2290-7.
DOI: https://doi.org/10.55563/clinexprheumatol/dt6klo
Barbhaiya M, Levine JM, Siegel CH, Bykerk VP, Jannat-Khah D, Mandl LA. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol 2022; 41: 1619-22.
DOI: https://doi.org/10.1007/s10067-021-05963-6
Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis 2022; 81: 695-709.
DOI: https://doi.org/10.1136/annrheumdis-2021-221490
Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, et al. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD Open 2022; 8: e002417.
DOI: https://doi.org/10.1136/rmdopen-2022-002417
Aochi S, Uehara M, Yamamoto M. IgG4-related disease emerging after COVID-19 mRNA vaccination: a case report. Intern Med 2023; 62: 1547-51.
DOI: https://doi.org/10.2169/internalmedicine.1125-22
Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 80: 930-42.
DOI: https://doi.org/10.1136/annrheumdis-2020-219498
Armağan B, Konak HE, Özdemir B, Apaydın H, Atalar E, Akyüz Dağlı P, et al. COVID-19 disease frequency, risk factors, and re-infection rates in patients with autoimmune rheumatic disease receiving rituximab. Int J Rheum Dis 2023; 26: 930-7.
DOI: https://doi.org/10.1111/1756-185X.14676
Bijlsma JW. EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs. Ann Rheum Dis 2021; 80: 411-2.
DOI: https://doi.org/10.1136/annrheumdis-2020-219773
How to Cite
Mastromanno, L., Giardina, F., Gattamelata, A., Colafrancesco, S., Truglia, S., Spinelli, F. R., … Priori, R. (2025). Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease. Reumatismo. https://doi.org/10.4081/reumatismo.2025.1744
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio, Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement , Reumatismo: Vol. 75 No. 1 (2023)
- A. Tincani, G. Fontana, C. Mackworth-Young, The history of antiphospholipid syndrome , Reumatismo: Vol. 74 No. 4 (2022)
- M.B. Ates, S. Karup, S. Ugurlu, Infliximab as successful treatment option in a case of adenosine deaminase 2 deficiency , Reumatismo: Vol. 75 No. 4 (2023)
- D.G. Fernández-Ávila, Ó.R. Vargas-Vanegas, L. Galindo-Rozo, Á. García-Peña, Ó. Muñoz-Velandia, Clinical characteristics and outcomes of patients with inflammatory and autoimmune rheumatological diseases admitted for intensive care in Colombia , Reumatismo: Vol. 75 No. 3 (2023)
- E. Molteni, C. Pirone, F. Ceccarelli, C. Castellani, C. Alessandri, M. Di Franco, V. Riccieri, F.R. Spinelli, R. Priori, R. Scrivo, F. Conti, Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort , Reumatismo: Vol. 76 No. 2 (2024)
- I. Acosta-Colman, Z. Morel, A. Ayala Lugo, V. Jolly, I. de Guillén, P. Langjahr, M. Vazquez, M.T Martínez de Filártiga, M.E. Acosta, Clinical features and genetic biomarkers associated with different phenotypes of systemic lupus erythematosus in Paraguayan patients , Reumatismo: Vol. 75 No. 2 (2023)
- C.G.V. de Carvalho, B. Bayeh, F.H.C. de Souza, R. Miossi, P.T. Inaoka, T. Matsushita, N. Mugii, S.K. Shinjo, Patients with anti-small ubiquitin-like modifier activating enzyme-positive dermatomyositis resembling antisynthetase syndrome with poor prognosis: a bicentric international retrospective study and literature review , Reumatismo: Early Access
- F.M. Galassi, L. Ingaliso, V. Papa, R. Lorenzi, E. Percivaldi, E. Varotto, On the early uses of the word ‘gout’: novel evidence and a critical assessment of the published literature , Reumatismo: Vol. 76 No. 2 (2024)
- G. El Hasbani, A.S.M. Jawad, I. Uthman, Rheumatology research output in the Arab World: despite the challenges , Reumatismo: Vol. 74 No. 3 (2022)
- Chiara Rizzo, Silvia Grazzini, Edoardo Conticini, Hector Chinoy, Roberto D’Alessandro, Federica Camarda, Luca Cantarini, Bruno Frediani, Giuliana Guggino, Lidia La Barbera, Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast , Reumatismo: Early Access
<< < 38 39 40 41 42 43 44 45 46 47 > >>
You may also start an advanced similarity search for this article.
